SlideShare une entreprise Scribd logo
1  sur  13
THE
VALUE OF
           GENERIC DRUG PRICING
GENERICS   AND AVAILABILITY




           Jim Keon, President
           Canadian Generic Pharmaceutical Association
In the last several years, the
price of generic drugs has
fallen dramatically.

The economic rationale for
using generics has never
been stronger.
TOTAL NUMBER OF PRESCRIPTIONS (%)
527 MILLION PRESCRIPTIONS


 GENERIC


                                    In 2012, of the 559 million
                                    prescriptions written in Canada,
                                    more than 63% of them were filled
                                    using generic drugs.
 BRAND
 -NAME
                                    The cost of these generic medicines
                                    represented only 24% of the $22
                                    billion dollars Canadians spent on
TOTAL MARKET COST (%)               prescription drugs.
21.1 BILLION DOLLARS
GENERIC                             While brand-name drugs were used
                                    to fill only 37% of prescriptions, they
                                    represented more than 76% of the
                                    total cost of prescriptions.

BRAND
-NAME




                                          source:
8-YEAR AVERAGE RETAIL PRICE - GENERIC vs. BRAND-NAME


    The average retail price of a generic prescription is $25.04
    versus $73.76 for a brand-name prescription.




     Over an eight-year period the average price of a brand-name
     drug prescription has risen from $60 to almost $74 which
     represents a 21% increase.
GENERIC vs. BRAND DRUG PRICING MODELS1


             BRITISH COLUMBIA




             ALBERTA




             SASKATCHEWAN




             MANITOBA




             ONTARIO




                                    All provinces provide for price exemptions.
 1. The data are as of fall 2012.
GENERIC vs. BRAND DRUG PRICING MODELS1


             QUEBEC




             NEW BRUNSWICK




             NOVA SCOTIA




             PRINCE EDWARD ISLAND




             NEWFOUNDLAND/LABRADOR




                                    All provinces provide for price exemptions.
 1. The data are as of fall 2012.
ADDITIONA PROVINCIAL COST SAVINGS FOR CANADIANS


      Six of the leading generic drugs on the market will be priced
      at 18% of brand-name drug price




      •   Atorvastatin
      •   Ramipril
      •   Venlafaxine
      •   Amlodipine
      •   Omeprazole
      •   Rabeprazole



              Representing 20% of generic drug sales in Canada
TENDERING GENERIC DRUGS: WHAT ARE THE RISKS?


     • Potential drug shortages because of less redundancy in
       the drug supply system.
     • Less patent litigation by generic manufacturers resulting
       in delayed availability of lower-cost generic drugs.
     • Less manufacturing of generic drugs in Canada.
     • Closure of some generic drugs manufacturing plants in
       Canada.
     • Less competition in the generic drug markets in Canada.
     • Less customer service offered by generic suppliers to
       pharmacies.
     • Less free customer service in the remaining pharmacies.


            Tendering Generic Drugs: What Are The Risks?
            October 24, 2012 – Professor Aidan Hollis, Department of Economics, University
            of Calgary, and Paul Grootendorst, University of Toronto, Faculty of Pharmacy
VALUE OF GENERIC MANUFACTURER’S LITIGATION


          EIGHT OF THE TEN TOP-SELLING DRUGS IN CANADA
       LAUNCHED AS A RESULT OF GENERIC COMPANY LITIGATION




               SAVINGS IN BILLIONS OF DOLLARS
INTERNATIONAL PRICE COMPARISONS


     INTERNATIONAL STUDIES ON PRICES OF GENERIC
     PHARMACEUTICAL PRODUCTS:

          • Measure manufacturer EX-factory prices. Prices DO
            NOT reflect total cost to payers in each market.

          • Prices are On-invoice Prices. Off-invoice
            discounts, free goods, rebates, etc. are not
            included.

          • Canadian prices DO NOT reflect manufacturer’s
            net prices – only the reimbursed/retail prices.

          • In Canada, retail/reimbursed prices include
            significant support for the services that community
            pharmacies provide to patients.

          • In other countries (e.g. United Sates) retailers
            purchase products from manufacturer then mark-up
            to sustainable prices. NOT the Canadian model.
GENERIC PRESCRIPTION MARKET - CANADA VS. U.S.




                                   In the United States generic
           80%                     drugs are dispensed to fill 80%
                                   of all prescriptions. In Canada
                                   it’s only 60%.


                                   If the use of generic drugs in
                                   Canada increased by 20% and
                                   matched the America
                                   levels, Canada’s health-care
                                   system would have saved
                                   nearly
                                   3-billion dollars in 2011.
           60%
Using independent, third party
data from IMS Brogan and the
Canadian Institute for Health
Information (CIHI) the CGPA has
calculated the savings available
to each province for every one
percent increase in the use of
generic drugs.

For every one percent increase
in the use of generic drugs in
Canada, Canadians save an
additional 262-million dollars.
Jim Keon, President
Canadian Generic Pharmaceutical Association

Contenu connexe

Tendances

Generics and the Animal Health Industry
Generics and the Animal Health IndustryGenerics and the Animal Health Industry
Generics and the Animal Health IndustryAmanda Boddington
 
Top 10 Biotech Companies & Market Share 2008
Top 10 Biotech Companies & Market Share 2008Top 10 Biotech Companies & Market Share 2008
Top 10 Biotech Companies & Market Share 2008Sheetal Narkar
 
Direct-to-Consumer Advertising in the Digital Age
Direct-to-Consumer Advertising in the Digital AgeDirect-to-Consumer Advertising in the Digital Age
Direct-to-Consumer Advertising in the Digital Agesggibson
 
Direct to consumer advertising
Direct to consumer advertisingDirect to consumer advertising
Direct to consumer advertisingGayathri Tangirala
 
Report on Gilead Sciences
Report on Gilead SciencesReport on Gilead Sciences
Report on Gilead SciencesRandy Acosta
 
Navigant: The Birth of An Orphan Biosimilar Market
Navigant: The Birth of An Orphan Biosimilar MarketNavigant: The Birth of An Orphan Biosimilar Market
Navigant: The Birth of An Orphan Biosimilar MarketJoanne Toran McHugh
 
Global Impact in Hepatitis-C Market with-In Pakistan and Internationally due ...
Global Impact in Hepatitis-C Market with-In Pakistan and Internationally due ...Global Impact in Hepatitis-C Market with-In Pakistan and Internationally due ...
Global Impact in Hepatitis-C Market with-In Pakistan and Internationally due ...Pharm Net
 
Nutraceutical-ExecutiveSummary
Nutraceutical-ExecutiveSummaryNutraceutical-ExecutiveSummary
Nutraceutical-ExecutiveSummaryTom McNulty
 
The Spiraling Cost of Specialty Drugs
The Spiraling Cost of Specialty DrugsThe Spiraling Cost of Specialty Drugs
The Spiraling Cost of Specialty DrugsWellDyne
 
Us biosimilars market opportunity & clinical pipeline analysis
Us biosimilars market opportunity & clinical pipeline analysisUs biosimilars market opportunity & clinical pipeline analysis
Us biosimilars market opportunity & clinical pipeline analysisRajesh Sarma
 
Direct to consumer pharmaceutical advertising
Direct to consumer pharmaceutical advertisingDirect to consumer pharmaceutical advertising
Direct to consumer pharmaceutical advertisingNazmul Hasan Mahmud
 
Direct To Consumer Advertising Of Prescription Drugs Pharmaceutical Industry
Direct To Consumer Advertising Of Prescription Drugs Pharmaceutical IndustryDirect To Consumer Advertising Of Prescription Drugs Pharmaceutical Industry
Direct To Consumer Advertising Of Prescription Drugs Pharmaceutical Industryjinender16
 
Rem de sivir - a classic analysis of desperate measures during desperate times
Rem de sivir - a classic analysis of desperate measures during desperate timesRem de sivir - a classic analysis of desperate measures during desperate times
Rem de sivir - a classic analysis of desperate measures during desperate timesDr Siddharth Dutta
 

Tendances (17)

Generics and the Animal Health Industry
Generics and the Animal Health IndustryGenerics and the Animal Health Industry
Generics and the Animal Health Industry
 
Top 10 Biotech Companies & Market Share 2008
Top 10 Biotech Companies & Market Share 2008Top 10 Biotech Companies & Market Share 2008
Top 10 Biotech Companies & Market Share 2008
 
India and global generics M&A Summary 2007
India and global generics M&A Summary 2007India and global generics M&A Summary 2007
India and global generics M&A Summary 2007
 
Direct-to-Consumer Advertising in the Digital Age
Direct-to-Consumer Advertising in the Digital AgeDirect-to-Consumer Advertising in the Digital Age
Direct-to-Consumer Advertising in the Digital Age
 
Direct to consumer advertising
Direct to consumer advertisingDirect to consumer advertising
Direct to consumer advertising
 
Report on Gilead Sciences
Report on Gilead SciencesReport on Gilead Sciences
Report on Gilead Sciences
 
Navigant: The Birth of An Orphan Biosimilar Market
Navigant: The Birth of An Orphan Biosimilar MarketNavigant: The Birth of An Orphan Biosimilar Market
Navigant: The Birth of An Orphan Biosimilar Market
 
Global Impact in Hepatitis-C Market with-In Pakistan and Internationally due ...
Global Impact in Hepatitis-C Market with-In Pakistan and Internationally due ...Global Impact in Hepatitis-C Market with-In Pakistan and Internationally due ...
Global Impact in Hepatitis-C Market with-In Pakistan and Internationally due ...
 
Nutraceutical-ExecutiveSummary
Nutraceutical-ExecutiveSummaryNutraceutical-ExecutiveSummary
Nutraceutical-ExecutiveSummary
 
The Spiraling Cost of Specialty Drugs
The Spiraling Cost of Specialty DrugsThe Spiraling Cost of Specialty Drugs
The Spiraling Cost of Specialty Drugs
 
Us biosimilars market opportunity & clinical pipeline analysis
Us biosimilars market opportunity & clinical pipeline analysisUs biosimilars market opportunity & clinical pipeline analysis
Us biosimilars market opportunity & clinical pipeline analysis
 
Drug advertising for presentation
Drug advertising for presentationDrug advertising for presentation
Drug advertising for presentation
 
Nature view
Nature viewNature view
Nature view
 
Direct to consumer pharmaceutical advertising
Direct to consumer pharmaceutical advertisingDirect to consumer pharmaceutical advertising
Direct to consumer pharmaceutical advertising
 
Direct To Consumer Advertising Of Prescription Drugs Pharmaceutical Industry
Direct To Consumer Advertising Of Prescription Drugs Pharmaceutical IndustryDirect To Consumer Advertising Of Prescription Drugs Pharmaceutical Industry
Direct To Consumer Advertising Of Prescription Drugs Pharmaceutical Industry
 
Rem de sivir - a classic analysis of desperate measures during desperate times
Rem de sivir - a classic analysis of desperate measures during desperate timesRem de sivir - a classic analysis of desperate measures during desperate times
Rem de sivir - a classic analysis of desperate measures during desperate times
 
The Rise of Organics
The Rise of OrganicsThe Rise of Organics
The Rise of Organics
 

Similaire à Jim Keon - Generic Drug Pricing and Availability

Prescription Medicines: Costs in Context June 2022
Prescription Medicines: Costs in Context June 2022Prescription Medicines: Costs in Context June 2022
Prescription Medicines: Costs in Context June 2022PhRMA
 
Prescription Medicines: Costs in Context - May 2023
Prescription Medicines: Costs in Context - May 2023Prescription Medicines: Costs in Context - May 2023
Prescription Medicines: Costs in Context - May 2023PhRMA
 
Prescription Medicines: Costs in Context - June 2022
Prescription Medicines: Costs in Context - June 2022Prescription Medicines: Costs in Context - June 2022
Prescription Medicines: Costs in Context - June 2022PhRMA
 
Prescription Medicines: Costs in Context - August2022
Prescription Medicines: Costs in Context - August2022Prescription Medicines: Costs in Context - August2022
Prescription Medicines: Costs in Context - August2022PhRMA
 
Webinar 2: Drug Launches: What Influences the Decision to Deploy New Medicines?
Webinar 2: Drug Launches: What Influences the Decision to Deploy New Medicines?Webinar 2: Drug Launches: What Influences the Decision to Deploy New Medicines?
Webinar 2: Drug Launches: What Influences the Decision to Deploy New Medicines?Canadian Organization for Rare Disorders
 
Prescription Medicines Costs in Context November 2019
Prescription Medicines Costs in Context November 2019Prescription Medicines Costs in Context November 2019
Prescription Medicines Costs in Context November 2019PhRMA
 
Prescription Medicines - Costs In Context March 2019
Prescription Medicines - Costs In Context March 2019Prescription Medicines - Costs In Context March 2019
Prescription Medicines - Costs In Context March 2019PhRMA
 
Prescription Medicines Costs in Context January 2020
Prescription Medicines Costs in Context January 2020Prescription Medicines Costs in Context January 2020
Prescription Medicines Costs in Context January 2020PhRMA
 
Prescription Medicines Costs in Context May 2020
Prescription Medicines Costs in Context May 2020Prescription Medicines Costs in Context May 2020
Prescription Medicines Costs in Context May 2020PhRMA
 
Prescription Medicines - Costs in Context January 2019
Prescription Medicines - Costs in Context January 2019Prescription Medicines - Costs in Context January 2019
Prescription Medicines - Costs in Context January 2019PhRMA
 
Zweig powerpoint on Palliative Care in Nursing Homes for Theme Session co-spo...
Zweig powerpoint on Palliative Care in Nursing Homes for Theme Session co-spo...Zweig powerpoint on Palliative Care in Nursing Homes for Theme Session co-spo...
Zweig powerpoint on Palliative Care in Nursing Homes for Theme Session co-spo...MedicineAndHealthUSA
 
Innovative Business Models in Global Healthcare - David Spellberg
Innovative Business Models in Global Healthcare - David SpellbergInnovative Business Models in Global Healthcare - David Spellberg
Innovative Business Models in Global Healthcare - David SpellbergDavid Spellberg
 
Prescription Medicines - Costs in Context - May 2018
Prescription Medicines - Costs in Context - May 2018Prescription Medicines - Costs in Context - May 2018
Prescription Medicines - Costs in Context - May 2018PhRMA
 
Prescription Medicines - Costs in Context - August 2018
Prescription Medicines - Costs in Context - August 2018Prescription Medicines - Costs in Context - August 2018
Prescription Medicines - Costs in Context - August 2018PhRMA
 
A Pharmacy Discussion
A Pharmacy DiscussionA Pharmacy Discussion
A Pharmacy DiscussionPremier Inc.
 
What if: A sliding scale were used to reimburse generic drugs to effectively ...
What if: A sliding scale were used to reimburse generic drugs to effectively ...What if: A sliding scale were used to reimburse generic drugs to effectively ...
What if: A sliding scale were used to reimburse generic drugs to effectively ...CFHI-FCASS
 
Prescription Medicines Costs in Context - June 2019
Prescription Medicines Costs in Context - June 2019Prescription Medicines Costs in Context - June 2019
Prescription Medicines Costs in Context - June 2019PhRMA
 
Prescription Medicines Costs in Context October 2020
Prescription Medicines Costs in Context October 2020Prescription Medicines Costs in Context October 2020
Prescription Medicines Costs in Context October 2020PhRMA
 
National Association of Attorneys Generals’ Presidential Initiative Summit Ap...
National Association of Attorneys Generals’ Presidential Initiative Summit Ap...National Association of Attorneys Generals’ Presidential Initiative Summit Ap...
National Association of Attorneys Generals’ Presidential Initiative Summit Ap...CVS Health
 

Similaire à Jim Keon - Generic Drug Pricing and Availability (20)

Prescription Medicines: Costs in Context June 2022
Prescription Medicines: Costs in Context June 2022Prescription Medicines: Costs in Context June 2022
Prescription Medicines: Costs in Context June 2022
 
Prescription Medicines: Costs in Context - May 2023
Prescription Medicines: Costs in Context - May 2023Prescription Medicines: Costs in Context - May 2023
Prescription Medicines: Costs in Context - May 2023
 
Prescription Medicines: Costs in Context - June 2022
Prescription Medicines: Costs in Context - June 2022Prescription Medicines: Costs in Context - June 2022
Prescription Medicines: Costs in Context - June 2022
 
Prescription Medicines: Costs in Context - August2022
Prescription Medicines: Costs in Context - August2022Prescription Medicines: Costs in Context - August2022
Prescription Medicines: Costs in Context - August2022
 
Webinar 2: Drug Launches: What Influences the Decision to Deploy New Medicines?
Webinar 2: Drug Launches: What Influences the Decision to Deploy New Medicines?Webinar 2: Drug Launches: What Influences the Decision to Deploy New Medicines?
Webinar 2: Drug Launches: What Influences the Decision to Deploy New Medicines?
 
Prescription Medicines Costs in Context November 2019
Prescription Medicines Costs in Context November 2019Prescription Medicines Costs in Context November 2019
Prescription Medicines Costs in Context November 2019
 
Prescription Medicines - Costs In Context March 2019
Prescription Medicines - Costs In Context March 2019Prescription Medicines - Costs In Context March 2019
Prescription Medicines - Costs In Context March 2019
 
Prescription Medicines Costs in Context January 2020
Prescription Medicines Costs in Context January 2020Prescription Medicines Costs in Context January 2020
Prescription Medicines Costs in Context January 2020
 
Prescription Medicines Costs in Context May 2020
Prescription Medicines Costs in Context May 2020Prescription Medicines Costs in Context May 2020
Prescription Medicines Costs in Context May 2020
 
Prescription Medicines - Costs in Context January 2019
Prescription Medicines - Costs in Context January 2019Prescription Medicines - Costs in Context January 2019
Prescription Medicines - Costs in Context January 2019
 
Drug Therapy Issues
Drug Therapy IssuesDrug Therapy Issues
Drug Therapy Issues
 
Zweig powerpoint on Palliative Care in Nursing Homes for Theme Session co-spo...
Zweig powerpoint on Palliative Care in Nursing Homes for Theme Session co-spo...Zweig powerpoint on Palliative Care in Nursing Homes for Theme Session co-spo...
Zweig powerpoint on Palliative Care in Nursing Homes for Theme Session co-spo...
 
Innovative Business Models in Global Healthcare - David Spellberg
Innovative Business Models in Global Healthcare - David SpellbergInnovative Business Models in Global Healthcare - David Spellberg
Innovative Business Models in Global Healthcare - David Spellberg
 
Prescription Medicines - Costs in Context - May 2018
Prescription Medicines - Costs in Context - May 2018Prescription Medicines - Costs in Context - May 2018
Prescription Medicines - Costs in Context - May 2018
 
Prescription Medicines - Costs in Context - August 2018
Prescription Medicines - Costs in Context - August 2018Prescription Medicines - Costs in Context - August 2018
Prescription Medicines - Costs in Context - August 2018
 
A Pharmacy Discussion
A Pharmacy DiscussionA Pharmacy Discussion
A Pharmacy Discussion
 
What if: A sliding scale were used to reimburse generic drugs to effectively ...
What if: A sliding scale were used to reimburse generic drugs to effectively ...What if: A sliding scale were used to reimburse generic drugs to effectively ...
What if: A sliding scale were used to reimburse generic drugs to effectively ...
 
Prescription Medicines Costs in Context - June 2019
Prescription Medicines Costs in Context - June 2019Prescription Medicines Costs in Context - June 2019
Prescription Medicines Costs in Context - June 2019
 
Prescription Medicines Costs in Context October 2020
Prescription Medicines Costs in Context October 2020Prescription Medicines Costs in Context October 2020
Prescription Medicines Costs in Context October 2020
 
National Association of Attorneys Generals’ Presidential Initiative Summit Ap...
National Association of Attorneys Generals’ Presidential Initiative Summit Ap...National Association of Attorneys Generals’ Presidential Initiative Summit Ap...
National Association of Attorneys Generals’ Presidential Initiative Summit Ap...
 

Plus de Pharmacare 2020

Pharmacare2020 Audience Polling Results
Pharmacare2020 Audience Polling ResultsPharmacare2020 Audience Polling Results
Pharmacare2020 Audience Polling ResultsPharmacare 2020
 
Steve Morgan - What Could Work? Will We Ever Get There?
Steve Morgan - What Could Work? Will We Ever Get There?Steve Morgan - What Could Work? Will We Ever Get There?
Steve Morgan - What Could Work? Will We Ever Get There?Pharmacare 2020
 
Michael McBane, Canadian Health Coalition - Visions for Pharmacare
Michael McBane, Canadian Health Coalition - Visions for PharmacareMichael McBane, Canadian Health Coalition - Visions for Pharmacare
Michael McBane, Canadian Health Coalition - Visions for PharmacarePharmacare 2020
 
Jordan Bateman, Canadian Taxpayers Federation - Visions for Pharmacare
Jordan Bateman, Canadian Taxpayers Federation - Visions for PharmacareJordan Bateman, Canadian Taxpayers Federation - Visions for Pharmacare
Jordan Bateman, Canadian Taxpayers Federation - Visions for PharmacarePharmacare 2020
 
Colleen Fuller - Pharmacare in Canada Today
Colleen Fuller - Pharmacare in Canada TodayColleen Fuller - Pharmacare in Canada Today
Colleen Fuller - Pharmacare in Canada TodayPharmacare 2020
 
Marc-Andre Gagnon - Pharmacare in Canada Today
Marc-Andre Gagnon - Pharmacare in Canada TodayMarc-Andre Gagnon - Pharmacare in Canada Today
Marc-Andre Gagnon - Pharmacare in Canada TodayPharmacare 2020
 
Michelle Boudreau - Patented Drug Pricing and Coverage
Michelle Boudreau - Patented Drug Pricing and CoverageMichelle Boudreau - Patented Drug Pricing and Coverage
Michelle Boudreau - Patented Drug Pricing and CoveragePharmacare 2020
 
Michael Law - Generic Drug Pricing and Availability
Michael Law - Generic Drug Pricing and AvailabilityMichael Law - Generic Drug Pricing and Availability
Michael Law - Generic Drug Pricing and AvailabilityPharmacare 2020
 
Mark Collison, Heart & Stroke Foundation - Visions for Pharmacare
Mark Collison, Heart & Stroke Foundation - Visions for PharmacareMark Collison, Heart & Stroke Foundation - Visions for Pharmacare
Mark Collison, Heart & Stroke Foundation - Visions for PharmacarePharmacare 2020
 
Marie-Claude Premont - Role of Private Insurance for Prescription Drugs in Ca...
Marie-Claude Premont - Role of Private Insurance for Prescription Drugs in Ca...Marie-Claude Premont - Role of Private Insurance for Prescription Drugs in Ca...
Marie-Claude Premont - Role of Private Insurance for Prescription Drugs in Ca...Pharmacare 2020
 
Diane McArthur - Patented Drug Pricing and Coverage
Diane McArthur - Patented Drug Pricing and CoverageDiane McArthur - Patented Drug Pricing and Coverage
Diane McArthur - Patented Drug Pricing and CoveragePharmacare 2020
 
Arthur Fabbro - Role of Private Insurance for Prescription Drugs in Canada
Arthur Fabbro - Role of Private Insurance for Prescription Drugs in CanadaArthur Fabbro - Role of Private Insurance for Prescription Drugs in Canada
Arthur Fabbro - Role of Private Insurance for Prescription Drugs in CanadaPharmacare 2020
 
Anna Reid, Canadian Medical Association - Visions for Pharmacare
Anna Reid, Canadian Medical Association - Visions for PharmacareAnna Reid, Canadian Medical Association - Visions for Pharmacare
Anna Reid, Canadian Medical Association - Visions for PharmacarePharmacare 2020
 
Barbara Walman - Pharmacare in Canada Today
Barbara Walman - Pharmacare in Canada TodayBarbara Walman - Pharmacare in Canada Today
Barbara Walman - Pharmacare in Canada TodayPharmacare 2020
 
Stephen Frank - Role of Private Insurance for Prescription Drugs in Canada
Stephen Frank - Role of Private Insurance for Prescription Drugs in CanadaStephen Frank - Role of Private Insurance for Prescription Drugs in Canada
Stephen Frank - Role of Private Insurance for Prescription Drugs in CanadaPharmacare 2020
 

Plus de Pharmacare 2020 (15)

Pharmacare2020 Audience Polling Results
Pharmacare2020 Audience Polling ResultsPharmacare2020 Audience Polling Results
Pharmacare2020 Audience Polling Results
 
Steve Morgan - What Could Work? Will We Ever Get There?
Steve Morgan - What Could Work? Will We Ever Get There?Steve Morgan - What Could Work? Will We Ever Get There?
Steve Morgan - What Could Work? Will We Ever Get There?
 
Michael McBane, Canadian Health Coalition - Visions for Pharmacare
Michael McBane, Canadian Health Coalition - Visions for PharmacareMichael McBane, Canadian Health Coalition - Visions for Pharmacare
Michael McBane, Canadian Health Coalition - Visions for Pharmacare
 
Jordan Bateman, Canadian Taxpayers Federation - Visions for Pharmacare
Jordan Bateman, Canadian Taxpayers Federation - Visions for PharmacareJordan Bateman, Canadian Taxpayers Federation - Visions for Pharmacare
Jordan Bateman, Canadian Taxpayers Federation - Visions for Pharmacare
 
Colleen Fuller - Pharmacare in Canada Today
Colleen Fuller - Pharmacare in Canada TodayColleen Fuller - Pharmacare in Canada Today
Colleen Fuller - Pharmacare in Canada Today
 
Marc-Andre Gagnon - Pharmacare in Canada Today
Marc-Andre Gagnon - Pharmacare in Canada TodayMarc-Andre Gagnon - Pharmacare in Canada Today
Marc-Andre Gagnon - Pharmacare in Canada Today
 
Michelle Boudreau - Patented Drug Pricing and Coverage
Michelle Boudreau - Patented Drug Pricing and CoverageMichelle Boudreau - Patented Drug Pricing and Coverage
Michelle Boudreau - Patented Drug Pricing and Coverage
 
Michael Law - Generic Drug Pricing and Availability
Michael Law - Generic Drug Pricing and AvailabilityMichael Law - Generic Drug Pricing and Availability
Michael Law - Generic Drug Pricing and Availability
 
Mark Collison, Heart & Stroke Foundation - Visions for Pharmacare
Mark Collison, Heart & Stroke Foundation - Visions for PharmacareMark Collison, Heart & Stroke Foundation - Visions for Pharmacare
Mark Collison, Heart & Stroke Foundation - Visions for Pharmacare
 
Marie-Claude Premont - Role of Private Insurance for Prescription Drugs in Ca...
Marie-Claude Premont - Role of Private Insurance for Prescription Drugs in Ca...Marie-Claude Premont - Role of Private Insurance for Prescription Drugs in Ca...
Marie-Claude Premont - Role of Private Insurance for Prescription Drugs in Ca...
 
Diane McArthur - Patented Drug Pricing and Coverage
Diane McArthur - Patented Drug Pricing and CoverageDiane McArthur - Patented Drug Pricing and Coverage
Diane McArthur - Patented Drug Pricing and Coverage
 
Arthur Fabbro - Role of Private Insurance for Prescription Drugs in Canada
Arthur Fabbro - Role of Private Insurance for Prescription Drugs in CanadaArthur Fabbro - Role of Private Insurance for Prescription Drugs in Canada
Arthur Fabbro - Role of Private Insurance for Prescription Drugs in Canada
 
Anna Reid, Canadian Medical Association - Visions for Pharmacare
Anna Reid, Canadian Medical Association - Visions for PharmacareAnna Reid, Canadian Medical Association - Visions for Pharmacare
Anna Reid, Canadian Medical Association - Visions for Pharmacare
 
Barbara Walman - Pharmacare in Canada Today
Barbara Walman - Pharmacare in Canada TodayBarbara Walman - Pharmacare in Canada Today
Barbara Walman - Pharmacare in Canada Today
 
Stephen Frank - Role of Private Insurance for Prescription Drugs in Canada
Stephen Frank - Role of Private Insurance for Prescription Drugs in CanadaStephen Frank - Role of Private Insurance for Prescription Drugs in Canada
Stephen Frank - Role of Private Insurance for Prescription Drugs in Canada
 

Jim Keon - Generic Drug Pricing and Availability

  • 1. THE VALUE OF GENERIC DRUG PRICING GENERICS AND AVAILABILITY Jim Keon, President Canadian Generic Pharmaceutical Association
  • 2. In the last several years, the price of generic drugs has fallen dramatically. The economic rationale for using generics has never been stronger.
  • 3. TOTAL NUMBER OF PRESCRIPTIONS (%) 527 MILLION PRESCRIPTIONS GENERIC In 2012, of the 559 million prescriptions written in Canada, more than 63% of them were filled using generic drugs. BRAND -NAME The cost of these generic medicines represented only 24% of the $22 billion dollars Canadians spent on TOTAL MARKET COST (%) prescription drugs. 21.1 BILLION DOLLARS GENERIC While brand-name drugs were used to fill only 37% of prescriptions, they represented more than 76% of the total cost of prescriptions. BRAND -NAME source:
  • 4. 8-YEAR AVERAGE RETAIL PRICE - GENERIC vs. BRAND-NAME The average retail price of a generic prescription is $25.04 versus $73.76 for a brand-name prescription. Over an eight-year period the average price of a brand-name drug prescription has risen from $60 to almost $74 which represents a 21% increase.
  • 5. GENERIC vs. BRAND DRUG PRICING MODELS1 BRITISH COLUMBIA ALBERTA SASKATCHEWAN MANITOBA ONTARIO All provinces provide for price exemptions. 1. The data are as of fall 2012.
  • 6. GENERIC vs. BRAND DRUG PRICING MODELS1 QUEBEC NEW BRUNSWICK NOVA SCOTIA PRINCE EDWARD ISLAND NEWFOUNDLAND/LABRADOR All provinces provide for price exemptions. 1. The data are as of fall 2012.
  • 7. ADDITIONA PROVINCIAL COST SAVINGS FOR CANADIANS Six of the leading generic drugs on the market will be priced at 18% of brand-name drug price • Atorvastatin • Ramipril • Venlafaxine • Amlodipine • Omeprazole • Rabeprazole Representing 20% of generic drug sales in Canada
  • 8. TENDERING GENERIC DRUGS: WHAT ARE THE RISKS? • Potential drug shortages because of less redundancy in the drug supply system. • Less patent litigation by generic manufacturers resulting in delayed availability of lower-cost generic drugs. • Less manufacturing of generic drugs in Canada. • Closure of some generic drugs manufacturing plants in Canada. • Less competition in the generic drug markets in Canada. • Less customer service offered by generic suppliers to pharmacies. • Less free customer service in the remaining pharmacies. Tendering Generic Drugs: What Are The Risks? October 24, 2012 – Professor Aidan Hollis, Department of Economics, University of Calgary, and Paul Grootendorst, University of Toronto, Faculty of Pharmacy
  • 9. VALUE OF GENERIC MANUFACTURER’S LITIGATION EIGHT OF THE TEN TOP-SELLING DRUGS IN CANADA LAUNCHED AS A RESULT OF GENERIC COMPANY LITIGATION SAVINGS IN BILLIONS OF DOLLARS
  • 10. INTERNATIONAL PRICE COMPARISONS INTERNATIONAL STUDIES ON PRICES OF GENERIC PHARMACEUTICAL PRODUCTS: • Measure manufacturer EX-factory prices. Prices DO NOT reflect total cost to payers in each market. • Prices are On-invoice Prices. Off-invoice discounts, free goods, rebates, etc. are not included. • Canadian prices DO NOT reflect manufacturer’s net prices – only the reimbursed/retail prices. • In Canada, retail/reimbursed prices include significant support for the services that community pharmacies provide to patients. • In other countries (e.g. United Sates) retailers purchase products from manufacturer then mark-up to sustainable prices. NOT the Canadian model.
  • 11. GENERIC PRESCRIPTION MARKET - CANADA VS. U.S. In the United States generic 80% drugs are dispensed to fill 80% of all prescriptions. In Canada it’s only 60%. If the use of generic drugs in Canada increased by 20% and matched the America levels, Canada’s health-care system would have saved nearly 3-billion dollars in 2011. 60%
  • 12. Using independent, third party data from IMS Brogan and the Canadian Institute for Health Information (CIHI) the CGPA has calculated the savings available to each province for every one percent increase in the use of generic drugs. For every one percent increase in the use of generic drugs in Canada, Canadians save an additional 262-million dollars.
  • 13. Jim Keon, President Canadian Generic Pharmaceutical Association